#China #Hangzhou #Innovent Biologics #NDA #Altruist Biologics

Altruist Biologics: A Milestone in Biologic Drug Manufacturing

In a significant leap for biopharmaceutical manufacturing, Altruist Biologics has announced that the National Medical Products Administration (NMPA) of China has accepted its new drug application (NDA) concerning the localized manufacturing of a biologic drug. This pivotal decision marks a crucial point for the multinational client involved and represents a strong support mechanism for the expedited approval process of the drug within the Chinese market.

Overview of the Achievement

Altruist Biologics, recognized globally as a premier contract development and manufacturing organization (CDMO) and a subsidiary of Innovent Biologics, has successfully forged a path to localization in the manufacturing of biologic therapies. This milestone is particularly remarkable as it aligns with the NMPA's newly introduced regulatory framework aimed at attracting global pharmaceutical companies to localize their production in China. The framework, established in 2024, encourages international firms to shift their manufacturing operations closer to the patient demographic they serve, helping to ensure better access to cutting-edge therapies.

Significance of Localized Manufacturing

Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, emphasized the importance of this development in his statement, attributing the NDA acceptance and priority review primarily to the collaborative effort between Altruist and its esteemed partner. He noted that local manufacturing not only enhances supply chain resilience but also broadens patient access to innovative medications within China. This strategic localization can reduce lead times for product availability and support the growing ethical demand for healthcare accessibility in the region.

Altruist's Advanced Capabilities

Located in Hangzhou, Altruist Biologics operates under stringent Good Manufacturing Practice (GMP) standards acknowledged by major regulatory authorities worldwide. The facility boasts an impressive total capacity of 172,000 liters for antibody manufacturing, with 80,000 liters operational across four state-of-the-art stainless-steel bioreactors. Additionally, a 2,000-liter single-use production line is currently under construction and anticipated to commence operations by mid-2027. Their capabilities extend to the development of antibody-drug conjugates and various bioconjugates, catering to both clinical and commercial production needs.

Altruist's commitment to quality and operational excellence is evident in its impressive track record: a >99.8% success rate achieved over 2,000 commercial batches and supporting the launch of 20 drugs through over 100 global regulatory filings—including notable approvals by the FDA, EMA, and TGA, among others.

Future Outlook

As Altruist Biologics continues to expand its operations, it is dedicated to incorporating new capabilities to maintain its competitive edge in the biomanufacturing sector. With over 1,400 employees, including leading scientists and experts across all areas of biologics production, Altruist is firmly positioned to further its mission of delivering high-qualitybiopharmaceuticals to patients worldwide.

This recent achievement not only reinforces Altruist's reputation as a leader in the biopharmaceutical industry but also underlines its role in transforming how global medicines are manufactured and distributed, particularly within populous markets like China. The company's proactive approach to localization is paving the way for enhanced patient care, ensuring that innovative therapies are no longer bound by geographical constraints but are accessible to those who need them most.